Details of the Drug

General Information of Drug (ID: DM4KDYJ)

Drug Name
Nortriptyline
Synonyms
Acetexa; Allegron; Altilev; Ateben; Avantyl; Aventyl; Demethylamitriptylene; Demethylamitriptyline; Demethylamitryptyline; Desitriptilina; Desitriptyline; Desmethylamitriptylin; Desmethylamitriptyline; Lumbeck; Noramitriptyline; Noritren; Nortrilen; Nortriptilina; Nortriptylinum; Nortryptiline; Nortryptyline; Pamelor; Psychostyl; Sensaval; Sesaval; Vividyl; AVENTYL HCL; Nortriptilina [DCIT]; Nortriptylene hydrochloride; Pamelor hydrochloride; Sensival Ventyl; NCI169453; Allegron (TN); Aventyl (TN); Norpress (TN); Nortrilen (TN); Nortriptyline (INN); Nortriptyline [INN:BAN]; Nortriptylinum [INN-Latin]; Pamelor (TN); Sensoval (TN); N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 263.4
Topological Polar Surface Area (xlogp) 4.5
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2-5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 72% [3]
Clearance
The sytemic clearance of drug is 54 L/h [5]
Elimination
Nortriptyline and its metabolites are mainly excreted in the urine, where only small amounts (2%) of the total drug is recovered as unchanged parent compound [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 26 hours [7]
Metabolism
The drug is metabolized via the demethylation and hydroxylation in the liver followed by glucuronic acid conjugation [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.34051 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.12% [9]
Vd
The volume of distribution (Vd) of drug is 1633 +/- 268 L [6]
Chemical Identifiers
Formula
C19H21N
IUPAC Name
N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
Canonical SMILES
CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
InChI
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
InChIKey
PHVGLTMQBUFIQQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4543
ChEBI ID
CHEBI:7640
CAS Number
72-69-5
DrugBank ID
DB00540
TTD ID
D04WFD
VARIDT ID
DR00398
INTEDE ID
DR1181
ACDINA ID
D00480

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Modulator [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [13]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [15]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.46E-01 -6.63E-03 -4.49E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.57E-01 9.43E-03 1.29E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 9.62E-01 2.57E-02 1.10E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 2.19E-01 1.72E-01 5.16E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nortriptyline
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Nortriptyline and Trimipramine. Depression [6A70-6A7Z] [68]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Nortriptyline and Cyclobenzaprine. Depression [6A70-6A7Z] [69]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Nortriptyline and Vilazodone. Depression [6A70-6A7Z] [69]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Nortriptyline and Nefazodone. Depression [6A70-6A7Z] [69]
Paroxetine DM5PVQE Major Decreased metabolism of Nortriptyline caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Nortriptyline and Selegiline. Depression [6A70-6A7Z] [71]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Nortriptyline and Vortioxetine. Depression [6A70-6A7Z] [69]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Nortriptyline and Isocarboxazid. Depression [6A70-6A7Z] [71]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Nortriptyline and Milnacipran. Depression [6A70-6A7Z] [69]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Nortriptyline and Escitalopram. Depression [6A70-6A7Z] [72]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Nortriptyline and Desvenlafaxine. Depression [6A70-6A7Z] [69]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Nortriptyline and OPC-34712. Depression [6A70-6A7Z] [68]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Nortriptyline and Phenelzine. Depression [6A70-6A7Z] [71]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Nortriptyline and Clomipramine. Depression [6A70-6A7Z] [68]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Nortriptyline and Trazodone. Depression [6A70-6A7Z] [69]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Nortriptyline and Amoxapine. Depression [6A70-6A7Z] [68]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Nortriptyline and Doxepin. Depression [6A70-6A7Z] [73]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Nortriptyline and Maprotiline. Depression [6A70-6A7Z] [68]
⏷ Show the Full List of 18 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Nortriptyline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Nortriptyline and Methylene blue. Acquired methaemoglobinaemia [3A93] [71]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Ivosidenib. Acute myeloid leukaemia [2A60] [74]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Midostaurin. Acute myeloid leukaemia [2A60] [75]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Idarubicin. Acute myeloid leukaemia [2A60] [75]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Daunorubicin. Acute myeloid leukaemia [2A60] [75]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Arn-509. Acute myeloid leukaemia [2A60] [76]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Gilteritinib. Acute myeloid leukaemia [2A60] [77]
Oliceridine DM6MDCF Moderate Additive serotonergic effects by the combination of Nortriptyline and Oliceridine. Acute pain [MG31] [78]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Nortriptyline and Scopolamine. Addictive disorder [6C50-6C5Z] [68]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Nortriptyline and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [73]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Nortriptyline and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [73]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [68]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Nortriptyline and Memantine. Alzheimer disease [8A20] [68]
Galantamine DMEO794 Moderate Antagonize the effect of Nortriptyline when combined with Galantamine. Alzheimer disease [8A20] [79]
Rivastigmine DMG629M Moderate Antagonize the effect of Nortriptyline when combined with Rivastigmine. Alzheimer disease [8A20] [79]
Donepezil DMIYG7Z Moderate Antagonize the effect of Nortriptyline when combined with Donepezil. Alzheimer disease [8A20] [79]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Nortriptyline and Ivabradine. Angina pectoris [BA40] [76]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Bepridil. Angina pectoris [BA40] [80]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Dronedarone. Angina pectoris [BA40] [75]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Nortriptyline and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [81]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [68]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Cilostazol. Arterial occlusive disease [BD40] [75]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Voriconazole. Aspergillosis [1F20] [75]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Nortriptyline and Desipramine. Attention deficit hyperactivity disorder [6A05] [68]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Ofloxacin. Bacterial infection [1A00-1C4Z] [82]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Clarithromycin. Bacterial infection [1A00-1C4Z] [75]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Nortriptyline and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [75]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Nortriptyline and Sparfloxacin. Bacterial infection [1A00-1C4Z] [82]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Nortriptyline and Linezolid. Bacterial infection [1A00-1C4Z] [83]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Gemifloxacin. Bacterial infection [1A00-1C4Z] [82]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Norfloxacin. Bacterial infection [1A00-1C4Z] [82]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Levofloxacin. Bacterial infection [1A00-1C4Z] [82]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Lomefloxacin. Bacterial infection [1A00-1C4Z] [75]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Telithromycin. Bacterial infection [1A00-1C4Z] [75]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Retigabine. Behcet disease [4A62] [75]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Nortriptyline and Cariprazine. Bipolar disorder [6A60] [68]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Nortriptyline and Loperamide. Bowel habit change [ME05] [84]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Eribulin. Breast cancer [2C60-2C6Y] [75]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Lapatinib. Breast cancer [2C60-2C6Y] [75]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Nortriptyline when combined with Acetylcholine. Cataract [9B10] [85]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [86]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [87]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Nortriptyline and Tiotropium. Chronic obstructive pulmonary disease [CA22] [87]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Nortriptyline and Revefenacin. Chronic obstructive pulmonary disease [CA22] [87]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Nortriptyline and Dihydrocodeine. Chronic pain [MG30] [78]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Nortriptyline and Levomilnacipran. Chronic pain [MG30] [69]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Nortriptyline and Olopatadine. Conjunctiva disorder [9A60] [88]
Mestranol DMG3F94 Minor Decreased metabolism of Nortriptyline caused by Mestranol. Contraceptive management [QA21] [89]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Halothane. Corneal disease [9A76-9A78] [75]
Alfentanil DMVO0UB Moderate Additive CNS depression effects by the combination of Nortriptyline and Alfentanil. Corneal disease [9A76-9A78] [78]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Probucol. Coronary atherosclerosis [BA80] [75]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Clofazimine. Crohn disease [DD70] [90]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Nortriptyline and Mifepristone. Cushing syndrome [5A70] [75]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Nortriptyline and Pasireotide. Cushing syndrome [5A70] [75]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Osilodrostat. Cushing syndrome [5A70] [76]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Nortriptyline and Ethanol. Cystitis [GC00] [91]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Nortriptyline and Mepenzolate. Digestive system disease [DE2Z] [68]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Nortriptyline and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [92]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Nortriptyline and Oxybutynine. Discovery agent [N.A.] [68]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [75]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Meclizine. Dizziness and giddiness [MB48] [68]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Deutetrabenazine. Dystonic disorder [8A02] [93]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Ingrezza. Dystonic disorder [8A02] [94]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Nortriptyline and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [95]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nortriptyline caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [96]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Nortriptyline caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Carbamazepine DMZOLBI Moderate Increased metabolism of Nortriptyline caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Mirabegron DMS1GYT Moderate Decreased metabolism of Nortriptyline caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [99]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Tolterodine. Functional bladder disorder [GC50] [68]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Pentamidine. Fungal infection [1F29-1F2F] [75]
Terbinafine DMI6HUW Moderate Decreased metabolism of Nortriptyline caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [100]
Miconazole DMPMYE8 Moderate Decreased metabolism of Nortriptyline caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [101]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Nortriptyline caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [101]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Nortriptyline and Propantheline. Gastric ulcer [DA60] [68]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Nortriptyline and Cisapride. Gastro-oesophageal reflux disease [DA22] [75]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Sunitinib. Gastrointestinal stromal tumour [2B5B] [75]
Acetazolamide DM1AF5U Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Nortriptyline caused by Acetazolamide mediated altered urine pH. Glaucoma [9C61] [102]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Nortriptyline when combined with Isoflurophate. Glaucoma [9C61] [85]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Nortriptyline when combined with Pilocarpine. Glaucoma [9C61] [85]
Carvedilol DMHTEAO Moderate Increased plasma concentrations of Nortriptyline and Carvedilol due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [97]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Nortriptyline and Procarbazine. Hodgkin lymphoma [2B30] [71]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [103]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Nortriptyline caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [104]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Nortriptyline and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [105]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Nortriptyline and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [106]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [75]
Verapamil DMA7PEW Moderate Decreased metabolism of Nortriptyline caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [107]
Givosiran DM5PFIJ Moderate Decreased metabolism of Nortriptyline caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [108]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Amantadine. Influenza [1E30-1E32] [109]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nortriptyline caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [110]
Propiomazine DMKY8V1 Moderate Increased plasma concentrations of Nortriptyline and Propiomazine due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [111]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Nortriptyline and ITI-007. Insomnia [7A00-7A0Z] [68]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Nortriptyline and Polyethylene glycol. Irritable bowel syndrome [DD91] [75]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Clidinium. Irritable bowel syndrome [DD91] [68]
Physostigmine DM2N0TO Moderate Antagonize the effect of Nortriptyline when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [79]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Nortriptyline caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [76]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Nortriptyline and Crizotinib. Lung cancer [2C25] [112]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Nortriptyline and Porfimer Sodium. Lung cancer [2C25] [113]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Nortriptyline and Ceritinib. Lung cancer [2C25] [75]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Nortriptyline caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [114]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Nortriptyline and Osimertinib. Lung cancer [2C25] [115]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Nortriptyline and Selpercatinib. Lung cancer [2C25] [76]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Nortriptyline and Lumefantrine. Malaria [1F40-1F45] [116]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Nortriptyline and Halofantrine. Malaria [1F40-1F45] [117]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Nortriptyline and Chloroquine. Malaria [1F40-1F45] [118]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Nortriptyline and Hydroxychloroquine. Malaria [1F40-1F45] [118]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [76]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Arsenic trioxide. Mature B-cell lymphoma [2A85] [119]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Vemurafenib. Melanoma [2C30] [75]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and LGX818. Melanoma [2C30] [120]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Nortriptyline caused by Ethinyl estradiol. Menopausal disorder [GA30] [89]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Nortriptyline and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [121]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Nortriptyline and Flibanserin. Mood disorder [6A60-6E23] [122]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Nortriptyline and Panobinostat. Multiple myeloma [2A83] [123]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Nortriptyline and Thalidomide. Multiple myeloma [2A83] [124]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Nortriptyline and Siponimod. Multiple sclerosis [8A40] [116]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Nortriptyline and Fingolimod. Multiple sclerosis [8A40] [75]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Nortriptyline and Ozanimod. Multiple sclerosis [8A40] [125]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Romidepsin. Mycosis fungoides [2B01] [75]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nortriptyline caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [76]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Nortriptyline and Nilotinib. Myeloproliferative neoplasm [2A20] [75]
Imatinib DM7RJXL Moderate Decreased metabolism of Nortriptyline caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [126]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Dasatinib. Myeloproliferative neoplasm [2A20] [127]
Modafinil DMYILBE Moderate Decreased metabolism of Nortriptyline caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [116]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Nortriptyline and Phenindamine. Nasopharyngitis [CA00] [68]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Dimenhydrinate. Nausea/vomiting [MD90] [68]
Rolapitant DM8XP26 Moderate Decreased metabolism of Nortriptyline caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [128]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Nortriptyline and Cyclizine. Nausea/vomiting [MD90] [68]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Nortriptyline and Granisetron. Nausea/vomiting [MD90] [75]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Nortriptyline and Dolasetron. Nausea/vomiting [MD90] [75]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Nortriptyline and Ondansetron. Nausea/vomiting [MD90] [75]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Nortriptyline and Bupropion. Nicotine use disorder [6C4A] [75]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Entrectinib. Non-small cell lung cancer [2C25] [116]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Nortriptyline and Sibutramine. Obesity [5B80-5B81] [129]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Nortriptyline and Lorcaserin. Obesity [5B80-5B81] [130]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Nortriptyline and Dexfenfluramine. Obesity [5B80-5B81] [69]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Levomethadyl Acetate. Opioid use disorder [6C43] [76]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Nortriptyline and Lofexidine. Opioid use disorder [6C43] [76]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Nortriptyline and Apraclonidine. Optic nerve disorder [9C40] [131]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Rucaparib. Ovarian cancer [2C73] [75]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Nortriptyline and Pentazocine. Pain [MG30-MG3Z] [78]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Nortriptyline and Dextropropoxyphene. Pain [MG30-MG3Z] [132]
Butorphanol DM5KYPJ Moderate Additive serotonergic effects by the combination of Nortriptyline and Butorphanol. Pain [MG30-MG3Z] [78]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Nortriptyline and Oxymorphone. Pain [MG30-MG3Z] [78]
Levorphanol DMGS80V Moderate Additive serotonergic effects by the combination of Nortriptyline and Levorphanol. Pain [MG30-MG3Z] [78]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Nortriptyline and Dezocine. Pain [MG30-MG3Z] [78]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Nortriptyline and Flavoxate. Pain [MG30-MG3Z] [68]
Nalbuphine DMOSQGU Moderate Additive serotonergic effects by the combination of Nortriptyline and Nalbuphine. Pain [MG30-MG3Z] [78]
Buprenorphine DMPRI8G Moderate Additive serotonergic effects by the combination of Nortriptyline and Buprenorphine. Pain [MG30-MG3Z] [78]
Hydrocodone DMQ2JO5 Moderate Additive serotonergic effects by the combination of Nortriptyline and Hydrocodone. Pain [MG30-MG3Z] [78]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Triclabendazole. Parasitic worm infestation [1F90] [75]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Nortriptyline and Safinamide. Parkinsonism [8A00] [125]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Nortriptyline and Rasagiline. Parkinsonism [8A00] [71]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Nortriptyline and Biperiden. Parkinsonism [8A00] [68]
Levodopa DMN3E57 Minor Altered absorption of Nortriptyline due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [133]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Pimavanserin. Parkinsonism [8A00] [134]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Nortriptyline and Orphenadrine. Parkinsonism [8A00] [68]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Apomorphine. Parkinsonism [8A00] [75]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Nortriptyline and Methylscopolamine. Peptic ulcer [DA61] [68]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Famotidine. Peptic ulcer [DA61] [116]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Nortriptyline and Macimorelin. Pituitary gland disorder [5A60-5A61] [135]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Lefamulin. Pneumonia [CA40] [136]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Degarelix. Prostate cancer [2C82] [76]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Nortriptyline caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [137]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Nilutamide. Prostate cancer [2C82] [76]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Enzalutamide. Prostate cancer [2C82] [76]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Relugolix. Prostate cancer [2C82] [76]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Bicalutamide. Prostate cancer [2C82] [76]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Nortriptyline and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [111]
Fluphenazine DMIT8LX Moderate Increased plasma concentrations of Nortriptyline and Fluphenazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [111]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Gatifloxacin. Respiratory infection [CA07-CA4Z] [138]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Quetiapine. Schizophrenia [6A20] [75]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Nortriptyline and Mesoridazine. Schizophrenia [6A20] [75]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Nortriptyline and Thioridazine. Schizophrenia [6A20] [139]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Nortriptyline and Aripiprazole. Schizophrenia [6A20] [68]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Nortriptyline and Iloperidone. Schizophrenia [6A20] [75]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Paliperidone. Schizophrenia [6A20] [75]
Perphenazine DMA4MRX Moderate Increased plasma concentrations of Nortriptyline and Perphenazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [111]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Nortriptyline and Molindone. Schizophrenia [6A20] [68]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Thiothixene. Schizophrenia [6A20] [68]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Nortriptyline and Risperidone. Schizophrenia [6A20] [68]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Nortriptyline and Amisulpride. Schizophrenia [6A20] [140]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Asenapine. Schizophrenia [6A20] [75]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Nortriptyline and Fentanyl. Sensation disturbance [MB40] [69]
Sufentanil DMU7YEL Moderate Additive serotonergic effects by the combination of Nortriptyline and Sufentanil. Sensation disturbance [MB40] [78]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Vardenafil. Sexual dysfunction [HA00-HA01] [75]
Armodafinil DMGB035 Moderate Decreased metabolism of Nortriptyline caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [116]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Nortriptyline and LEE011. Solid tumour/cancer [2A00-2F9Z] [75]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Nortriptyline and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [75]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [76]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [75]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [75]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Nortriptyline and Adenosine. Supraventricular tachyarrhythmia [BC81] [75]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Lenvatinib. Thyroid cancer [2D10] [75]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Cabozantinib. Thyroid cancer [2D10] [76]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Nortriptyline and Papaverine. Tonus and reflex abnormality [MB47] [141]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Nortriptyline and Tizanidine. Tonus and reflex abnormality [MB47] [142]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Atropine. Unspecific substance harmful effect [NE6Z] [68]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Astemizole. Vasomotor/allergic rhinitis [CA08] [75]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [68]
Methdilazine DMAUHQX Moderate Increased plasma concentrations of Nortriptyline and Methdilazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [111]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Nortriptyline and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [68]
Trimeprazine DMEMV9D Moderate Increased plasma concentrations of Nortriptyline and Trimeprazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [143]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Nortriptyline and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [68]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Nortriptyline and Acrivastine. Vasomotor/allergic rhinitis [CA08] [68]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Nortriptyline and Azatadine. Vasomotor/allergic rhinitis [CA08] [68]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Procainamide. Ventricular tachyarrhythmia [BC71] [75]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Nortriptyline and Propafenone. Ventricular tachyarrhythmia [BC71] [144]
Flecainide DMSQDLE Moderate Decreased metabolism of Nortriptyline caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [144]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Nortriptyline and Amiodarone. Ventricular tachyarrhythmia [BC71] [75]
⏷ Show the Full List of 210 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Butylparaben E00142 7184 Antimicrobial preservative
Dimethylphenylcarbinol E00216 12053 Flavoring agent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben E00543 23663626 Antimicrobial preservative
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Edetate calcium disodium E00487 6093170 Complexing agent
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate E00395 110800 Emollient; Opacifying agent; Surfactant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium propionate E00445 2723816 Antimicrobial preservative
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Aluminum lake E00504 9989226 Other agent
Dimethicone 350 E00706 Not Available Antifoaming agent; Emollient; Water-repelling agent
FD&C green no. 3 E00689 Not Available Colorant
Shellac E00695 Not Available Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
⏷ Show the Full List of 28 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nortriptyline 10 mg capsule 10 mg Oral Capsule Oral
Nortriptyline 25 mg capsule 25 mg Oral Capsule Oral
Nortriptyline 50 mg capsule 50 mg Oral Capsule Oral
Nortriptyline 75 mg capsule 75 mg Oral Capsule Oral
Nortriptyline Hydrochloride 50mg capsule 50mg Capsule Oral
Nortriptyline Hydrochloride 25mg capsule 25mg Capsule Oral
Nortriptyline Hydrochloride 10mg/capsule capsule 10mg/capsule Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2404).
2 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Dawling S, Crome P, Braithwaite R: Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clin Pharmacokinet. 1980 Jul-Aug;5(4):394-401. doi: 10.2165/00003088-198005040-00007.
6 MedSafe NZ data sheet: Nortriptyline tablets
7 Pharmacokinetic aspects on once-daily nortriptyline administration. Neuropsychobiology. 1980;6(1):34-41. doi: 10.1159/000117730.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 Cytochrome P-450 activities in human and rat brain microsomes. Brain Res. 2000 Feb 14;855(2):235-43.
12 A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
13 In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998 Aug;23(4):247-55.
14 Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4.
15 Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
18 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
19 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
20 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
21 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
23 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
24 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
25 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
26 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
27 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
28 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
29 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
30 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
31 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
32 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
33 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
34 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
35 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
36 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
37 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
38 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
39 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
40 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
41 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
42 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
43 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
44 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
45 Drug Interactions Flockhart Table
46 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
47 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
48 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
49 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
50 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
51 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
52 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
53 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
54 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
55 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
56 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
57 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
58 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
59 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
60 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
61 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
62 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
63 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
64 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
65 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
66 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
67 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
68 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
69 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
70 Albers LJ, Reist C, Helmeste D, Vu R, Tang SW "Paroxetine shifts imipramine metabolism." Psychiatry Res 59 (1996): 189-96. [PMID: 8930024]
71 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
72 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
73 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
74 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
75 Canadian Pharmacists Association.
76 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
77 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
78 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
79 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
80 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
81 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
82 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
83 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
84 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
85 Multum Information Services, Inc. Expert Review Panel.
86 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
87 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
88 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
89 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
90 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
91 Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
92 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
93 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
94 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
95 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
96 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
97 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
98 Brosen K, Kragh-Sorensen P "Concomitant intake of nortriptyline and carbamazepine." Ther Drug Monit 15 (1993): 258-60. [PMID: 8333008]
99 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
100 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
101 Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9. [PMID: 10750939]
102 Gram LF, Kofod B, Christiansen J, Rafaelsen OJ "Imipramine metabolism: pH-dependent distribution and urinary excretion." Clin Pharmacol Ther 12 (1971): 239-44. [PMID: 5554940]
103 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
104 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
105 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
106 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
107 Hermann DJ, Krol TF, Dukes GE, et al "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine." J Clin Pharmacol 32 (1992): 176-83. [PMID: 1613128]
108 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
109 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
110 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
111 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
112 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
113 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
114 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
115 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
116 Cerner Multum, Inc. "Australian Product Information.".
117 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
118 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
119 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
120 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
121 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
122 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
123 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
124 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
125 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
126 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
127 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
128 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
129 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
130 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
131 Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
132 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
133 Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
134 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
135 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
136 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
137 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
138 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
139 Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
140 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
141 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
142 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
143 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
144 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]